The Attorney General Consumer and Prescriber Education Grant Program (CPGP) was created to educate health care professionals about pharmaceutical industry marketing practices and to provide tools for accessing unbiased sources of information about prescription drugs. The program is funded through the 2004 Attorneys General settlement resolving allegations that Warner Lambert violated state consumer protection laws when promoting Neurontin, an epilepsy drug, for off-label uses.
The Office of Oregon Health Policy and Research is one of 24 first-round grant recipients, and has collaborated with the Oregon State University College of Pharmacy to develop a curriculum to educate healthcare professionals to critically view pharmaceutical marketing strategies and to access unbiased evidence-based drug comparisons to encourage quality and cost–effective prescribing.
For more information about the CPGP, go to the Oregon Health Policy and Research web site.
These online courses are available free of charge to licensed medical prescribers in the nation and may be taken for continuing medical education credit.* To view the modules of other grant participants, please visit the Online Prescriber Education Network (OPEN) website at the Federation of State Medical Boards.
*This activity has been planned and implemented in accordance with the Essential Areas & Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Texas Southwestern Medical Center and the Federation of State Medical Boards Research and Education Foundation. The University of Texas Southwestern Medical Center is accredited by the ACCME to provide continuing medical education for physicians.
Academic Detailing presentation (PowerPoint)
Sample profiling form (PDF)
The following are Quicktime .mov files of the ads themselves:
Brand Name vs. Generic Drugs (TV spot #1)
Generic Drugs (TV spot #2)
Designer Drugs (TV spot #3)
This work was made possible by a grant from the state Attorney General Consumer and Prescriber Education Program which is funded by the multi-state settlement of consumer fraud claims regarding the marketing of the prescription drug Neurontin.